BioHarvest Sciences Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St

April 02, 2025

BioHarvest Sciences (NASDAQ:BHST) Full Year 2024 Results

Key Financial Results

Revenue: US$25.2m (up 99% from FY 2023).
Net loss: US$12.9m (loss widened by 2.8% from FY 2023).
US$0.80 loss per share.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

earnings-and-revenue-growth — NasdaqGM:BHST Earnings and Revenue Growth April 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

BioHarvest Sciences EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.9%.

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the US.

Performance of the American Personal Products industry.

The company's shares are down 3.9% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for BioHarvest Sciences you should be aware of, and 1 of them is a bit unpleasant.

If you're looking to trade BioHarvest Sciences, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if BioHarvest Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.